NCT00870181

ADV-TK Improves Outcome of Recurrent High-Grade Glioma

Adenovirus-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Administration Improves Outcome of Recurrent High-Grade Glioma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 47 (actual)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for patients with these tumors remains poor despite advances in diagnosis and standard therapies such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy highlight its efficacy and safety for glioma patients. This clinical trial was conducted to assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV administration in patients with recurrent high-grade glioma.

Conditions

• Malignant Glioma of Brain
• Glioblastoma

Interventions

Type	Name	Description
BIOLOGICAL	ADV-TK/GCV	gene therapy
PROCEDURE	Surgery
DRUG	systemic chemotherapy

Timeline

• Start date: 2008-01-01
• Primary completion: 2011-12-01
• Completion: 2012-12-01
• First posted: 2009-03-27
• Last updated: 2013-06-25

Locations

1 site across 1 country: China